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Summary 
The opioid peptide dynorphin has been 
described as widely distributed in CNS when 
measured by RIA. Our previous immunohistochemi- 
cal studies have only demonstrated dynorphin 
cells as those containing AVP. We now report 
the specific localization of dynorphin through- 
out the neuraxis. Further, dynorphin and alpha- 
neo-endorphin have been co-localized to the same 
magnocellular neurosecretory cells in hypo- 
thalamus. We report agreement with the findings 
of others and extend them to include a cell 
group in dorsomedial hypothalmus, further 
strengthening the association between dynorphin 
and alpha-neo-endorphin. 
The potent opioid peptide dynorphin has been the subject of 
intense anatomical, physiological and biochemical study. Its 
distribution and connectivity in CNS has been very difficult to 
precisely determine. Data from RIA studies have shown that 
dynorphin can be found throughout the neuraxis (1,2,3). Yet 
anatomical studies have reported a much more limited distribu- 
tion (4,5,6,7). We previously demonstrated that dynorphin was 
located in vasopressin (AVP) containing cells of the supraoptic 
(SON) and paraventricular (PVN) nuclei. Recently with the 
purification and sequencing of dynorphin through residue number 
seventeen (8,9), it has been possible to develop antisera 
against the COOH-terminus of dynorphin-17. The problem of 
potential cross-reactivity between dynorphin antisera and the 
several opioid peptides has been solved by developing an 
antiserum against a non-enkephalin fragment of dynorphin (i.e., 
residues 7-17). 
We employed several antisera (against dynorphin-17 and 
dynorphin-(l-13) from Dr. Avram Goldstein, and dynorphin-(7-17)) 
in these studies. All animals were Sprague-Dawley rats either 
pretreated with colchicine (400 ug, icv, 48 hrs prior to 
sacrifice) or untreated. Immunocytochemistry was carried out as 
reported elsewhere (4). 
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FIG. 1 
Dynorphin is distributed widely throughout the 
neuraxis. For example, immunoreactive dynorphin 
terminals are localized to some olfactory bulb (OLF) 
glomeruli (A), while dynorphin-positive perikarya and 
fibers are seen in the periaqueductal gray (PAG) (B), 
lateral parabrachial nucleus (PBN) (C), and nucleus 
tractus solitarius (NTS) (D). Arrows in (A) point to 
the connection between the olfactory nerve layer (ONL) 
and a glomerulus (G). Bar is 50 um. 
The results of the use of all three types of dynorphin 
antisera are highly consistent. They demonstrate a broad set of 
dynorphin positive cells and fibers (see Fig. i) at every level 
of the neuraxis (I0). For example, some of the glomeruli of the 
olfactory bulb are stained for dynorphin, where as others are 
not. Fibers are seen in the globus pallidus; cells and fibers 
are seen in the central nucleus of the amygdala with a heavy set 
of fibers in the stria terminals. Within the hippoc ampal 
formation, dynorphin-positive fibers are seen in the dentate 
gyrus and mossy fiber projection to areas CA3 and CA2. The 
hypothalamus has a distribution of cells and fibers, reported 
previously by us, to be magnocellular in origin (4,5). Further, 
we have been able to see a large dynorphin-positive cell group 
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FIG. 2 
Dynorphin (A,C,E) and alpha-neo-endorphin (B,D,F) are 
co-localized in the same cells of the supraoptic 
nucleus (SON) (A,B) , paraventricular nucleus (PVN) 
( C, D) and thee cel is in the dorsomedial/lateral 
hypothalmic areas (E,F). The same n~bered cells can 
be seen stained with both antisera in A and B; C and 
D; and E and F. Stars are in common vessels for each 
area. Bar is 20 um. 
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in the posterior hypothalamus beginning in the dorsomedial 
nucleus extending laterally past the fornix into the lateral 
hypothalamic area. Fibers were also visible in the ventromedial 
nucleus, with cells and fibers appearing in the arcuate nucleus. 
Progressing caudally, one can see heavy fiber staining in the 
zona reticulata of the substantia nigra and cells in the ventral 
aspect of the PAG. At the level of the fourth ventricle, it is 
possible to stain cells in the n. parabrachialis. Other brain 
stem and spinal areas included cells in the nucleus tractus 
solitarius, n. cuneatus, and dorsal horn. All demonstrations 
were blockable with dynorphin-17 and not with any other opioid 
peptide tested. 
The other aspect of this paper involves the anatomy of 
alpha-neo-endorphin structures. Immunocytochemical studies of 
alpha-neo-endorphin place it in the posterior pituitary, SON and 
PVN with AVP and dynorphin (6,7). While it has a very similar 
distribution to that of dynorphin in the magnocellular nuclei, 
the biosynthesis of this peptide is not as yet clearly linked to 
dynorphin. Many peptides are co-localized in the same neurons 
but not synthesized from the same precursor. However, 
co-localization of peptides in several different cell groups may 
provide stronger evidence for synthesis from the precursor. 
Accordingly, we have studied alpha-neo-endorphin and dynorphin 
in both the magnocellular nuclei as well as the dorsal 
medial-lateral cell groups. As shown in Fig. 2, both peptides 
can be localized to both cell types. These data provide 
increased support for the hypothesis of a common biosynthetic 
route for dynorphin and alpha-neo-endorphin. 
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